ANGO - AngioDynamics FY 2023 EPS guidance falls short of consensus

• AngioDynamics said that its fiscal year 2023 earnings per share guidance is $0.01-$0.06, below consensus expectation of $0.08.
• The medical technology company focused on the body’s vascular system noted that its FY 2023 revenue estimate is $342M to $348M vs. consensus of ~$337.7M.
• In FY 2022 Q4, AngioDynamics ( NASDAQ: ANGO ) achieved a revenue beat and came in-line on earnings .
• For the full FY 2022, net sales were $316.2M, an increase of 8.7% compared to FY 2021. Med Tech sales were $78.7M, a 41.2% increase.
• Its loss for the year was $26.5M ($0.68 per share) compared to $31.5M ($0.82 per share) in the year-ago period.
• AngioDynamics ( ANGO ) ended the quarter (May 31) with cash of $28.8M.
• Seeking Alpha's Quant Rating views AngioDynamics ( ANGO ) as a buy with high marks for profitability, momentum, and growth .

For further details see: